Apple Fred S, Jaffe Allan S, Collinson Paul, Mockel Martin, Ordonez-Llanos Jordi, Lindahl Bertil, Hollander Judd, Plebani Mario, Than Martin, Chan M H M
Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN, USA.
Cardiovascular Division, Mayo Clinic, Rochester,MN, USA.
Clin Biochem. 2015 Mar;48(4-5):201-3. doi: 10.1016/j.clinbiochem.2014.08.021. Epub 2014 Sep 7.
In 2011, the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) was formed, with the purpose of providing evidence based educational materials to assist all biomarker users, i.e. laboratorians, clinicians, researchers, in-vitro diagnostics and regulatory agencies, in better understanding important analytical and clinical aspects of established and novel cardiac biomarkers for use in clinical practice and research. The goal of the task force was to promulgate the same information conjointly through the in vitro diagnostic industry to the laboratory, emergency department and cardiologists. The initial undertaking of the TF-CB, which is comprised of laboratory medicine scientists, emergency medicine physicians and cardiologists, was to address two key issues pertaining to implementing high-sensitivity cardiac troponin (hs-cTn) assays in clinical practice: the 99th percentile upper reference limit (URL) and calculating serial change values in accord with the Universal Definition of AMI. The highlights of both concepts from IFCC statements are described.
2011年,国际临床化学与检验医学联合会(IFCC)心脏生物标志物临床应用特别工作组(TF-CB)成立,旨在提供循证教育材料,以帮助所有生物标志物使用者,即检验人员、临床医生、研究人员、体外诊断和监管机构,更好地理解用于临床实践和研究的已确立和新型心脏生物标志物的重要分析和临床方面。该特别工作组的目标是通过体外诊断行业联合向实验室、急诊科和心脏病专家传播相同的信息。TF-CB由检验医学科学家、急诊医学医生和心脏病专家组成,其最初的任务是解决临床实践中实施高敏心肌肌钙蛋白(hs-cTn)检测的两个关键问题:第99百分位上限参考值(URL)以及根据急性心肌梗死的通用定义计算连续变化值。文中描述了IFCC声明中这两个概念的要点。